Skip to main content
. 2017 Apr 25;55(5):1350–1368. doi: 10.1128/JCM.02137-16

TABLE 4.

Comparison of susceptibility phenotype with that predicted by genotypea

Source of breakpointsb Drug Drug code(s) Isolate D-01, S. Typhimurium
 Isolate D-18, S. Derby
 Isolate D-59, S. Albany
 Isolate C-02, S. I 4,5,12: i:−
Genotype predicted by WGS Phenotype based on COMPAN2F Phenotype based on NARMs Genotype predicted by WGS Phenotype based on COMPAN2F Phenotype based on NARMs Genotype predicted by WGS Phenotype based on COMPAN2F Phenotype based on NARMs Genotype predicted by WGS Phenotype based on COMPAN2F Phenotype based on NARMs
A Amikacin AMI S S — S S — S S — S S —
A Amoxicillin-clavulanic acid (2:1 ratio) AMC, AUG2 S NI S S NI S R NI R S NI S
A Ampicillin AMP R NI R R NI R R NI R R NI R
D Azithromycin AZI S — S S — S S — S S — S
A Cefazolin FAZ S S — S S — R NI — S S —
E Cefovecin FOV S S — S S — R R — S S —
C Cefoxitin FOX S S S S S S R R R S S S
C Cefpodoxime POD S S — S S — R R — S S —
C Ceftriaxone AXO S — S S — S R — R S — S
D Ceftiofur XNL, TIO S S S S S S R R R S S S
A Cephalothin CEP S S — S S — S NI — S S —
A Chloramphenicol CHL R R R S S S S S S S S S
C Ciprofloxacin CIP S — S S — S S — S S — S
C Doxycycline DOX S S — R R — S S — S S —
A Enrofloxacin ENRO S S — S S — S S — S S —
A Gentamicin GEN S S S S S S S S S S S S
A Imipenem IMI S S — S S — S S — S S —
C Kanamycin KAN R — R R — R S — — S — —
A Marbofloxacin MAR S S — S S — S S — S S —
C Nalidixic acid NAL S — S S — S S — S S — S
D Streptomycin STR R — R R — R S — S R — R
A Sulfisoxazole FIS R — R R — R S — S S — S
A Tetracycline TET R — R R — R S — S S — S
C Ticarcillin TIC R R — R R — R R — R R —
B Ticarcillin-clavulanic acid constant 2 TIM2 Sc Rc — S S — R R — S S —
A Trimethoprim-sulfamethoxazole SXT, COT S S S S S S S S S S S S
a

S, susceptible to drug; R, resistant to drug; NI, no interpretation (panel's highest drug concentration was lower than drug's breakpoint); –, drug not available on that plate.

b

Breakpoints from the following sources were used for interpretation: CLSI M31-A3 (108) (A), CLSI VET01-S2E (109) (B), CLSI M100-S24 (110) (C), NARMS (114) (D), and EMA (115) (E).

c

Discrepancy between phenotype and predicted genotype.